NewAmsterdam Pharma Enters Material Definitive Agreement

TL;DR

NAMS signed a big deal on Aug 12, 2025. Details in new 8-K.

AI Summary

On August 12, 2025, NewAmsterdam Pharma Company N.V. entered into a material definitive agreement. The filing also includes financial statements and exhibits related to this agreement.

Why It Matters

This filing indicates a significant new agreement for NewAmsterdam Pharma, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can introduce new risks and opportunities that are not yet fully understood.

Key Players & Entities

• NewAmsterdam Pharma Company N.V. (company) — Registrant
• August 12, 2025 (date) — Date of earliest event reported

FAQ

Filing Documents

• nams-20250812.htm (8-K) — 59KB
• 0000950170-25-109387.txt ( ) — 205KB
• nams-20250812.xsd (EX-101.SCH) — 54KB
• nams-20250812_htm.xml (XML) — 6KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. On August 12, 2025, NewAmsterdam Pharma B.V. (the "Subsidiary"), a subsidiary of NewAmsterdam Pharma Company N.V. (the "Company"), entered into a Supply Agreement (the "Supply Agreement") with A. Menarini International Licensing S.A. ("Menarini"), as contemplated by the License Agreement between Menarini and the Subsidiary dated June 23, 2022, as amended (the "License Agreement"). Under the terms of the Supply Agreement, the Subsidiary agreed to supply Menarini with obicetrapib monotherapy and obicetrapib and ezetimibe fixed-dose combination finished products in bulk tablet form (the "Drug Products"). The Subsidiary will initially be Menarini's exclusive supplier of the Drug Products and fulfill purchase orders based on periodic volume forecasts that Menarini is required to provide, a portion of which will be binding. The price to be paid by Menarini will be based on a specified mark-up to the Subsidiary's "cost of goods sold" for the supplied Drug Products as determined in accordance with the Supply Agreement, subject to periodic adjustments. The Supply Agreement also provides that the parties will initiate a process to transfer manufacturing of the Drug Products to Menarini or to a designated third-party contract manufacturer. In connection with the manufacturing transfer, the Subsidiary granted Menarini a non-exclusive, non-transferable license under the Company's patents and know-how to manufacture finished Drug Products. The term of the Supply Agreement continues for the duration of the term of the License Agreement unless terminated earlier as set forth in Supply Agreement. The Subsidiary may terminate the Supply Agreement for convenience upon advance 120 days' written notice to Menarini, provided that the effective date of such a termination must follow the earlier of (i) completion of the manufacturing transfer described above and (ii) two years after the initiation of such transfer. Either party m

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NewAmsterdam Pharma Company N.V. Date: August 15, 2025 By: /s/ Michael Davidson Name: Michael Davidson, M.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR